Brigitta U. Mueller, MD, MHCM

For patients who are ineligible for erythropoiesis-stimulating agents, luspatercept-aamt offers a new approach.

Since blinatumomab was first approved in 2014 for relapsed/refractory acute lymphoblastic leukemia, the field has seen rapid progress. Now, a growing number of BiTEs are under development for different solid tumors and hematologic malignancies.

Increased understanding of the tumor microenvironment, the importance of molecular abnormalities, and the signaling pathways of cytokines has finally yielded more effective, tumor-specific therapies.